Price to FCFE (P/FCFE)
Paying user area
Try for free
Cigna Group pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Liquidity Ratios
- Analysis of Reportable Segments
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cigna Group for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to Equity (FCFE)
Cigna Group, FCFE calculation
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Net Cash Provided by Operating Activities
- The net cash provided by operating activities experienced a notable decline from 10,350 million US dollars in 2020 to 7,191 million US dollars in 2021, indicating a reduction in the cash generated from core business operations during this period. However, this figure showed a recovery trend in the following years, increasing to 8,656 million in 2022 and further rising to a peak of 11,813 million in 2023. In 2024, there was a slight decrease to 10,363 million, but the level remained substantially higher than the initial years, suggesting improved operational cash flow performance overall after the dip in 2021.
- Free Cash Flow to Equity (FCFE)
- The free cash flow to equity demonstrated a different pattern, starting at 4,520 million US dollars in 2020 and increasing significantly to 6,558 million in 2021. This increase contrasts with the decline observed in net operating cash flow for the same period, indicating potentially improved capital expenditure management or other financing activities impacting FCFE. In 2022, FCFE decreased to 4,802 million but then sharply rebounded to 9,962 million in 2023, almost doubling the 2022 value. The upward momentum continued slightly in 2024 with a minor increase to 10,017 million. This overall growth indicates enhanced liquidity available to equity shareholders, driven mainly by strong cash flow generation and effective capital allocation in the latter years.
- Overall Trends and Insights
- The financial data reveal an initial challenge in 2021 marked by a downturn in operating cash flow, which recovered strongly in subsequent years. While net cash from operations fluctuated, FCFE showed a more robust upward trend post-2021, highlighting strategic financial management aimed at maximizing shareholder returns. The recovery and growth in free cash flow to equity surpassing operational cash flow improvements suggest a focus on optimizing investments and financing to increase equity value.
Price to FCFE Ratio, Current
Cigna Group, current P/FCFE calculation, comparison to benchmarks
| No. shares of common stock outstanding | |
| Selected Financial Data (US$) | |
| Free cash flow to equity (FCFE) (in millions) | |
| FCFE per share | |
| Current share price (P) | |
| Valuation Ratio | |
| P/FCFE | |
| Benchmarks | |
| P/FCFE, Competitors1 | |
| Abbott Laboratories | |
| Elevance Health Inc. | |
| Intuitive Surgical Inc. | |
| Medtronic PLC | |
| UnitedHealth Group Inc. | |
| P/FCFE, Sector | |
| Health Care Equipment & Services | |
| P/FCFE, Industry | |
| Health Care | |
Based on: 10-K (reporting date: 2024-12-31).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Cigna Group, historical P/FCFE calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Free cash flow to equity (FCFE) (in millions)2 | ||||||
| FCFE per share3 | ||||||
| Share price1, 4 | ||||||
| Valuation Ratio | ||||||
| P/FCFE5 | ||||||
| Benchmarks | ||||||
| P/FCFE, Competitors6 | ||||||
| Abbott Laboratories | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| P/FCFE, Sector | ||||||
| Health Care Equipment & Services | ||||||
| P/FCFE, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Data adjusted for splits and stock dividends.
3 2024 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =
4 Closing price as at the filing date of Cigna Group Annual Report.
5 2024 Calculation
P/FCFE = Share price ÷ FCFE per share
= ÷ =
6 Click competitor name to see calculations.
- Share Price
- The share price experienced a general upward trend from 2020 to 2023, increasing from $209.34 to a peak of $336.14. However, in 2024, there was a noticeable decline to $302.92, indicating a partial correction after several years of growth.
- Free Cash Flow to Equity (FCFE) per Share
- FCFE per share showed a mostly positive trajectory throughout the period. It rose significantly from $12.85 in 2020 to $20.43 in 2021, then dipped to $16.17 in 2022. From 2022 onwards, it demonstrated strong growth, reaching $34.08 in 2023 and further increasing to $36.60 in 2024, which suggests improving cash generation capacity available to shareholders.
- Price to FCFE Ratio (P/FCFE)
- The P/FCFE ratio fluctuated more markedly. It started relatively high at 16.3 in 2020, declined sharply to 10.98 in 2021, and then rose again to 18.23 in 2022. Subsequently, it declined steadily to 9.86 in 2023 and further to 8.28 in 2024. This indicates that the market's valuation of the company relative to its FCFE per share became more conservative over time, particularly after 2022, despite the increasing FCFE.
- Overall Analysis
- The company's financial performance, as indicated by FCFE per share, improved substantially over the five-year span, especially in the last two years. The share price reflected positive momentum until 2023 but experienced a pullback in 2024. The decreasing P/FCFE ratio towards the end of the period suggests that the market may be pricing the shares more cautiously relative to the cash flow yields, potentially due to changing risk perceptions or broader market conditions. The combination of rising FCFE and a falling P/FCFE ratio may highlight an increasing attractiveness in valuation terms despite the drop in share price from the peak.